Filing Flows › Arbutus Biopharma (ABUS) › How it makes money
How Arbutus Biopharma (ABUS) makes money
Arbutus Biopharma (ABUS) made $1.0M of revenue in the second quarter 2026 (Q2 2026), -91% from a year earlier. Revenue from collaborations and licenses brought in $632K (62%); Collaborations and licenses brought in $202K (20%); Non-cash royalty revenue brought in $180K (18%).
Drawing the Sankey…
Revenue by segment, Q2 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Revenue from collaborations and licenses | $632K | 62.3% | -100% | — |
| Collaborations and licenses | $202K | 19.9% | -1% | -98% |
| Non-cash royalty revenue | $180K | 17.8% | -0.6% | -66% |
Where each dollar of revenue goes
| Line | Q2 2026 | % of revenue |
|---|---|---|
| Revenue | $1.0M | 100.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q2 2026 | $1.0M | -91% |
| Q1 2026 | $179M | 102× |
| Q4 2025 | $1.1M | -33% |
| Q3 2025 | $529K | -60% |
| Q2 2025 | $10.7M | +522% |
| Q1 2025 | $1.8M | +15% |
| Q4 2024 | $1.6M | -27% |
From Arbutus Biopharma's 10-Q filed Aug 12, 2026 (on EDGAR).
Questions
How does Arbutus Biopharma make money?
Arbutus Biopharma (ABUS) made $1.0M of revenue in the second quarter 2026 (Q2 2026), -91% from a year earlier. Revenue from collaborations and licenses brought in $632K (62%); Collaborations and licenses brought in $202K (20%); Non-cash royalty revenue brought in $180K (18%).
What is Arbutus Biopharma's biggest business?
Revenue from collaborations and licenses: $632K in the second quarter 2026, 62% of revenue.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.